Post-AcuteDesperate Families Search for Affordable Home Care
There is little help from the government for families who need a home health aide, unless they are poor.
PayerMedicare Advantage Increasingly Popular With Seniors — But Not Hospitals and Doctors
Payers have enticed just over half of all Medicare beneficiaries ? or nearly 31 million people ? to their plans...
Clinical CareBack Pain? Bum Knee? Be Prepared to Wait for a Physical Therapist
The cost of getting trained is out of proportion to the pay.
Post-AcuteWhy Long-Term Care Insurance Falls Short for So Many
For decades, the industry severely underestimated how many policyholders would use their coverage.
Extra Fees Drive Assisted Living Profits
Highly profitable facilities often charge $5,000 a month or more and then layer on fees at every step.
NursingFacing Financial Ruin as Costs Soar for Elder Care
Millions of families are facing such daunting life choices ? and potential financial ruin ? as the escalating costs of...
Clinical CareWho Will Care for Older Adults? We've Plenty of Know-How but Too Few Specialists
Despite the surging older population, there are fewer geriatricians now (just over 7,400) than in 2000 (10,270).
PharmaPatient Advocates Rap 'Greedy' PhRMA IRA Lawsuits
As consumers struggle with soaring drug prices, AstraZeneca Q3 profits doubled to $1.37 billion.
Clinical CareDoubts Abound About a New Alzheimer's Blood Test
Alzheimer's researchers aren't convinced the Quest test is backed by sound scientific research.
PayerTiny, Rural Hospitals Feel the Pinch as Medicare Advantage Plans Grow
MA plans have become dubious payers for many hospitals, which report the insurers are often slow to pay or don't...
PayerFeds Rein In Use of Predictive Software That Limits Care for Medicare Advantage Patients
AI tools often predict a patient's date of discharge, which coincides with the date their insurer cuts off coverage, even...
PharmaThe Real Costs of the New Alzheimer's Drug, Most of Which Will Fall to Taxpayers
Medicare and Medicaid patients will make up 92% of the market for lecanemab.